About this trial
Critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine.
Because it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed.
This trial is investigating if the marker urinary dickkopf-3 (uDKK3) allows an early prediction of a sudden decrease of kidney function.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients treated on the intensive care units of Saarland University Hospital.
Disqualifiers
Patients on renal replacement treatment before admission to the intensive care unit.
Patients with chronic kidney disease stage CKD G3b or below.
Known kidney disease.
Kidney transplantation.
Trial population
Patients on intensive care units of the Saarland University Hospital.
Trial design
Case-only
Prospective
Treatments tested in this trial
DKK-3
Diagnostic testDKK-3-Urine measurement
Treatment groups
Trial outcomes
Primary outcomes
Urinary dickkopf-3
Urinary dickkopf-3
Estimated Glomerula Filtration Rate
Estimated Glomerula Filtration Rate by CKD-EPI-formula.
Secondary outcomes
Mortality
Number of patients who die during the observational period.
End Stage Renal Disease
Number of patients with initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation).
Length of renal replacement therapy
Length of time patients receive renal replacement therapy for chronic kidney injury.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.